G1 Therapeutics to Evaluate Trilaciclib (G1T28) in Combination with Immune Checkpoint Inhibitor in Small-Cell Lung Cancer

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2016 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. a clinical-stage oncology company, announced today a clinical trial collaboration with Genentech, a member of the Roche Group. A Phase 2 clinical trial is expected to begin in the first half of 2017 and will evaluate the combination of Genentech’s immune checkpoint, anti-PD-L1 antibody Tecentriq® (atezolizumab) with G1’s CDK4/6 inhibitor trilaciclib (G1T28) as a first-line treatment for patients with small-cell lung cancer (SCLC) receiving chemotherapy.

Trilaciclib is a potential first-in-class, short-acting intravenous CDK4/6 inhibitor in development to preserve hematopoietic stem cells and enhance immune system function during chemotherapy. Tecentriq is an anti-PD-L1 monoclonal antibody designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. The Phase 2 study will explore the potential affects of the combination with trilaciclib on the efficacy of anti-PD-L1 inhibition given with chemotherapy in patients with newly diagnosed SCLC.

Preliminary results from two ongoing Phase 1b/2a trials of trilaciclib in combination with chemotherapy in SCLC have demonstrated anti-tumor activity, including a complete response and multiple partial responses. The treatment has been well-tolerated with no febrile neutropenia. In preclinical studies, trilaciclib significantly increased efficacy and overall survival in combination with oxaliplatin and anti-PD-L1 in syngeneic mouse-tumor models.

“We are excited that this combination regimen of trilaciclib plus Tecentriq may benefit patients with small-cell lung cancer, a disease with tremendous unmet medical need,” said Mark Velleca, MD, PhD, Chief Executive Officer of G1 Therapeutics. “Trilaciclib has demonstrated its ability to preserve the immune system from damage by chemotherapy and to enhance T cell activation, which may augment anti-tumor immunity and be a powerful complement to Tecentriq.”

Financial terms of the non-exclusive collaboration have not been disclosed.

About Trilaciclib

Trilaciclib (G1T28) is a potential first-in-class, short-acting IV CDK4/6 inhibitor being developed to preserve hematopoietic stem cells and enhance immune system function during chemotherapy. Trilaciclib has the potential to significantly improve the treatment outcomes of patients receiving chemotherapy.

Trilaciclib is being studied in two Phase 1b/2a proof-of-concept trials in patients with small-cell lung cancer: a study in newly diagnosed, treatment-naive patients (NCT02499770), and a study in previously treated patients (NCT02514447).

About G1 Therapeutics, Inc.

G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in people with cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.

Visit www.g1therapeutics.com for more information.

CONTACT: G1 Investor Contact:                                          
Mark Velleca, MD, PhD                 
G1 Therapeutics                                               

G1 Media Contact:
Laura Bagby                      
6 Degrees Communications


You May Also Like

アイデラ・ファーマシューティカルズ (Idera Pharmaceuticals)、実施中のPD-1治療抵抗性の転移性メラノーマ患者におけるイピリムマブ併用の腫瘍内IMO-2125の第1相試験の用量漸増試験で、有望なデータを報告

- PD-1治療抵抗性の皮膚メラノーマの3人の患者に奏効し、そのうちの1人では完全奏効 (CR) を実現 - - IMO-2125の臨床開発の優先度が高くなったため、同社はB細胞リンパ腫治療のためのIMO-8400の開発を一時中止 - セッツ州ケンブリッジおよびペンシルベニア州エクストン, Sept. 27, 2016 (GLOBE NEWSWIRE) ...


賓夕法尼亞州普利茅斯會議, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc。(NASDAQ: INO)今日宣佈該公司最近發表的三項DNA編碼單克隆抗體(dMAb™)技術研究結果令人印象深刻。 在臨床前模擬試驗中治療心血管疾病和預防伊波拉病毒和萊姆病致病細菌的感染。利用最近公佈的幾項獲肯定的臨床前數據,Inovio計劃在明年初期獲得全面外部資金,開始研究dMAb產品對傳染病療效的首次臨床試驗。 傳統的單克隆抗體佔據當今醫藥市場中的最主要的部分,每年藥品銷售額超過500億美元,治療範圍從癌症和傳染病到炎症和心血管疾病。憑藉其合成設計和體內自行生產方法,Inovio的dMAb產品可為這一重要類別的藥物提供新穎、突破性的方法。當dMAb直接遞送到體內時,DNA質粒所提供的遺傳指令會使患者自身的細胞成為製造治療性抗體的工廠。 Inovio已獲得超過6,000萬美元的非稀釋性撥款資金,讓Inovio能在過去幾年推展其dMAb平台。最近,Bill ...